Genmab — Transaction in Own Shares 2022

Jul 25, 2022

6-K 1 tmb-20220725x6k.htm 6-K Enhanced HTML document created with Toppan Merrill Bridge 9.14.0.96 Created on: 7/25/2022 12:21:04 PM (UTC) HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF JULY 2022

COMMISSION FILE NUMBER 001-38976

Genmab A/S (Exact name of Registrant as specified in its charter)

Kalvebod Brygge 43

1560 Copenhagen V

Denmark

+45 70 20 27 28 (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ⌧ Form 40-F ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1)

Yes ◻ No ⌧

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7)

Yes ◻ No ⌧

This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

nthony	​	​
​	GENMAB A/S
​	​	​
​	BY:	/s/ Anthony Pagano
​	​	Name: Anthony Pagano
​	​	Title: Executive Vice President & Chief Financial Officer

DATE: July 25, 2022

EXHIBIT INDEX

O
Exhibit	Description of Exhibit
​	​
99.1	Company Announcement Dated July 25, 2022: Transactions in connection with share buy-back program
99.1(a)	Appendix: Transactions July 18-22, 2022